HRP20210352T1 - Terapeutska sredstva za liječenje bolesti povezanih s neželjenom proliferacijom stanica - Google Patents
Terapeutska sredstva za liječenje bolesti povezanih s neželjenom proliferacijom stanica Download PDFInfo
- Publication number
- HRP20210352T1 HRP20210352T1 HRP20210352TT HRP20210352T HRP20210352T1 HR P20210352 T1 HRP20210352 T1 HR P20210352T1 HR P20210352T T HRP20210352T T HR P20210352TT HR P20210352 T HRP20210352 T HR P20210352T HR P20210352 T1 HRP20210352 T1 HR P20210352T1
- Authority
- HR
- Croatia
- Prior art keywords
- treatment
- therapeutic agents
- cell proliferation
- diseases associated
- undesired cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2093—Leukaemia inhibitory factor [LIF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200900928A ES2363358B1 (es) | 2009-04-03 | 2009-04-03 | Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable. |
| EP16155009.0A EP3045474B1 (en) | 2009-04-03 | 2010-04-06 | Therapeutic agents for the treatment of diseases associated with undesired cell proliferation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210352T1 true HRP20210352T1 (hr) | 2021-05-28 |
Family
ID=42342718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210352TT HRP20210352T1 (hr) | 2009-04-03 | 2021-03-02 | Terapeutska sredstva za liječenje bolesti povezanih s neželjenom proliferacijom stanica |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US10100112B2 (https=) |
| EP (2) | EP3045474B1 (https=) |
| JP (5) | JP6207836B2 (https=) |
| KR (6) | KR20180079470A (https=) |
| CN (2) | CN102574918A (https=) |
| AU (1) | AU2010233791B2 (https=) |
| BR (1) | BRPI1015369A2 (https=) |
| CA (1) | CA2757680C (https=) |
| CY (1) | CY1124148T1 (https=) |
| DK (1) | DK3045474T3 (https=) |
| EA (1) | EA201101450A1 (https=) |
| ES (2) | ES2363358B1 (https=) |
| HR (1) | HRP20210352T1 (https=) |
| HU (1) | HUE054196T2 (https=) |
| IL (1) | IL215467A (https=) |
| LT (1) | LT3045474T (https=) |
| MX (1) | MX336903B (https=) |
| PL (1) | PL3045474T3 (https=) |
| PT (1) | PT3045474T (https=) |
| SG (2) | SG10202010568RA (https=) |
| SI (1) | SI3045474T1 (https=) |
| SM (1) | SMT202100153T1 (https=) |
| WO (1) | WO2010115868A2 (https=) |
| ZA (1) | ZA201107215B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1904093T3 (pl) * | 2005-07-19 | 2018-12-31 | Stemgen S.P.A. | Hamowanie przez bmp-4 zdolności do tworzenia guzów przez komórki macierzyste guza |
| EP2371860A1 (en) | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
| JP2015071566A (ja) * | 2013-10-03 | 2015-04-16 | 住友ベークライト株式会社 | Ｆｇｆ４遺伝子増幅腫瘍の医薬組成物 |
| JP2017507969A (ja) * | 2014-03-11 | 2017-03-23 | ゴーダーヴァリ バイオリファイナリーズ リミテッド | がん幹細胞標的化合物 |
| CA3151221C (en) * | 2014-06-30 | 2026-01-13 | Altor Bioscience Corporation | Il-15-based molecules and methods of use thereof |
| CN106687134A (zh) * | 2014-09-10 | 2017-05-17 | 加利福尼亚大学董事会 | 通过抗hLIF抗体靶向K‑RAS介导的信号转导通路和恶性肿瘤 |
| EP3067422B1 (en) * | 2015-03-13 | 2024-07-31 | Sabanci Üniversitesi | Ct-1 inhibitors |
| EP3273983B1 (en) | 2015-03-23 | 2021-05-05 | Evestra, Inc. | Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents |
| EP3173483A1 (en) | 2015-11-27 | 2017-05-31 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Agents for the treatment of diseases associated with undesired cell proliferation |
| US10583191B2 (en) | 2016-12-19 | 2020-03-10 | Mosaic Biomedicals Slu | Antibodies against LIF and uses thereof |
| EP3555132B1 (en) * | 2016-12-19 | 2023-11-15 | Medimmune Limited | Antibodies against lif and uses thereof |
| AU2019269131B2 (en) * | 2018-05-14 | 2024-02-22 | Fundació Privada Institució Catalana De Recerca I Estudis Avançats | Antibodies against LIF and dosage forms thereof |
| MA52300A (fr) * | 2018-06-18 | 2021-04-21 | Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron | Combinaison d'inhibiteurs de lif et d'agents anti-néoplasiques à base de platine à utiliser dans le traitement du cancer |
| AU2019291305B2 (en) * | 2018-06-18 | 2024-03-21 | Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats | Methods for improving response to anti-LIF antibody treatment in individuals with cancer |
| WO2020056349A2 (en) * | 2018-09-13 | 2020-03-19 | Evestra, Inc. | Lif/lifr antagonist oncology and nonmalignant diseases |
| IL287220B2 (en) * | 2019-04-17 | 2026-03-01 | Univ Hiroshima | A therapeutic agent for urological cancer characterized by administering an IL-6 inhibitor in combination with a CCR2 inhibitor |
| CN111020030A (zh) * | 2019-12-03 | 2020-04-17 | 中山大学 | 一种骨肉瘤干细胞标志物及其应用、试剂盒 |
| EP3988116A1 (en) * | 2020-10-23 | 2022-04-27 | Consejo Superior De Investigaciones Científicas (CSIC) | Methods and compositions for the treatment of hematologic malignancies |
| CN120507517B (zh) * | 2025-05-21 | 2026-04-10 | 浙江省肿瘤医院 | 用于评估宫颈癌鳞癌和腺癌特异性的预后分子标记物及其应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| ATE115999T1 (de) | 1987-12-15 | 1995-01-15 | Gene Shears Pty Ltd | Ribozyme. |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| GB9004890D0 (en) * | 1990-03-05 | 1990-05-02 | Heath John K | Leukaemia inhibitory factor |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| JPH05304986A (ja) * | 1992-04-28 | 1993-11-19 | Tosoh Corp | ｇｐ１３０蛋白質に対するモノクロ−ナル抗体 |
| AU4231393A (en) * | 1992-05-08 | 1993-12-13 | Genentech Inc. | Antibodies to leukemia inhibitory factor |
| GB9413316D0 (en) | 1994-07-01 | 1994-08-24 | Cancer Res Campaign Tech | Novel proteins |
| US6251588B1 (en) | 1998-02-10 | 2001-06-26 | Agilent Technologies, Inc. | Method for evaluating oligonucleotide probe sequences |
| US20050147609A1 (en) | 1998-05-15 | 2005-07-07 | Genentech, Inc. | Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| HU229520B1 (en) * | 1999-02-12 | 2014-01-28 | Scripps Research Inst | Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies |
| US6110462A (en) | 1999-03-03 | 2000-08-29 | The Scripps Research Institute | Enzymatic DNA molecules that contain modified nucleotides |
| US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| CA2480052A1 (en) | 2002-04-01 | 2003-10-16 | Human Genome Sciences, Inc. | Antibodies that specifically bind to gmad |
| EP2236614A3 (en) * | 2002-08-15 | 2011-01-26 | Genzyme Corporation | Brain endothelial cell expression patterns |
| US20060078533A1 (en) * | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2004067778A2 (en) * | 2003-01-28 | 2004-08-12 | University Of South Florida | Differentially expressed genes in large granular lymphocyte leukemia |
| WO2005030803A1 (en) * | 2003-09-29 | 2005-04-07 | The Walter And Eliza Hall Institute Of Medical Research | Therapeutic molecules |
| EP1752536A4 (en) * | 2004-05-11 | 2008-04-16 | Alphagen Co Ltd | POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME |
| AR073231A1 (es) * | 2008-08-29 | 2010-10-20 | Genentech Inc | Metodos diagnosticos y tratamientos para los tumores independientes del vegf (factor de crecimiento endotelial vascular) |
| EP2371860A1 (en) * | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
| US10583191B2 (en) * | 2016-12-19 | 2020-03-10 | Mosaic Biomedicals Slu | Antibodies against LIF and uses thereof |
-
2009
- 2009-04-03 ES ES200900928A patent/ES2363358B1/es not_active Withdrawn - After Issue
-
2010
- 2010-04-06 CA CA2757680A patent/CA2757680C/en active Active
- 2010-04-06 PT PT161550090T patent/PT3045474T/pt unknown
- 2010-04-06 CN CN2010800246730A patent/CN102574918A/zh active Pending
- 2010-04-06 JP JP2012502710A patent/JP6207836B2/ja active Active
- 2010-04-06 KR KR1020187018827A patent/KR20180079470A/ko not_active Ceased
- 2010-04-06 LT LTEP16155009.0T patent/LT3045474T/lt unknown
- 2010-04-06 HU HUE16155009A patent/HUE054196T2/hu unknown
- 2010-04-06 KR KR1020207017470A patent/KR102373754B1/ko active Active
- 2010-04-06 PL PL16155009T patent/PL3045474T3/pl unknown
- 2010-04-06 KR KR1020117026088A patent/KR20120100703A/ko not_active Ceased
- 2010-04-06 BR BRPI1015369-1A patent/BRPI1015369A2/pt not_active Application Discontinuation
- 2010-04-06 MX MX2011010425A patent/MX336903B/es active IP Right Grant
- 2010-04-06 US US13/138,804 patent/US10100112B2/en active Active
- 2010-04-06 KR KR1020227007752A patent/KR20220035978A/ko not_active Ceased
- 2010-04-06 ES ES16155009T patent/ES2864639T3/es active Active
- 2010-04-06 CN CN201711070081.2A patent/CN107964043A/zh active Pending
- 2010-04-06 WO PCT/EP2010/054499 patent/WO2010115868A2/en not_active Ceased
- 2010-04-06 AU AU2010233791A patent/AU2010233791B2/en not_active Ceased
- 2010-04-06 EA EA201101450A patent/EA201101450A1/ru unknown
- 2010-04-06 KR KR1020197022597A patent/KR20190093691A/ko not_active Ceased
- 2010-04-06 SI SI201032059T patent/SI3045474T1/sl unknown
- 2010-04-06 EP EP16155009.0A patent/EP3045474B1/en active Active
- 2010-04-06 SM SM20210153T patent/SMT202100153T1/it unknown
- 2010-04-06 SG SG10202010568RA patent/SG10202010568RA/en unknown
- 2010-04-06 EP EP10713619A patent/EP2414394A2/en not_active Ceased
- 2010-04-06 KR KR1020177030504A patent/KR20170121319A/ko not_active Ceased
- 2010-04-06 SG SG2011071834A patent/SG175032A1/en unknown
- 2010-04-06 DK DK16155009.0T patent/DK3045474T3/da active
-
2011
- 2011-10-02 IL IL215467A patent/IL215467A/en active IP Right Grant
- 2011-10-03 ZA ZA2011/07215A patent/ZA201107215B/en unknown
-
2015
- 2015-09-11 JP JP2015178986A patent/JP2016040255A/ja active Pending
-
2018
- 2018-08-14 JP JP2018152551A patent/JP2019006784A/ja active Pending
- 2018-08-28 US US16/115,191 patent/US20190211095A1/en not_active Abandoned
-
2020
- 2020-02-04 JP JP2020016672A patent/JP2020090522A/ja active Pending
- 2020-08-24 US US17/001,530 patent/US11999782B2/en active Active
-
2021
- 2021-03-02 HR HRP20210352TT patent/HRP20210352T1/hr unknown
- 2021-03-18 CY CY20211100232T patent/CY1124148T1/el unknown
- 2021-11-17 JP JP2021186785A patent/JP7197665B2/ja active Active
-
2024
- 2024-05-01 US US18/652,603 patent/US20240400667A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210352T1 (hr) | Terapeutska sredstva za liječenje bolesti povezanih s neželjenom proliferacijom stanica | |
| EA201201192A1 (ru) | Тиенопиримидины, содержащие замещенную алкильную группу, предназначенные для фармацевтических композиций | |
| CU20140025A7 (es) | Pirimidinas anilladas sustituidas | |
| PH12017501908B1 (en) | Human anti-cd27 antibodies, methods and uses | |
| BR112016011485A2 (pt) | Derivados de imidazopiridazina como moduladores de atividade de tnf | |
| UY35115A (es) | Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso | |
| WO2014066486A3 (en) | Biomarker for use in treating anemia | |
| HK1203356A1 (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
| JO3091B1 (ar) | مشتقات حمض 3- فنيل بروبيونيك متفرعة واستخداماتها | |
| ECSP12012310A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| TN2012000335A1 (en) | Antibody formulation and therapeutic regimens | |
| TW201711676A (en) | Ferric citrate dosage forms | |
| BRPI1010718A2 (pt) | sistemas modelo e regimes de tratamento para tratar doença neurológica. | |
| EA201201193A1 (ru) | Тиенопиримидины, содержащие гетероциклоалкил, предназначенные для фармацевтических композиций | |
| PH12012502129A1 (en) | New combination therapy in treatment of oncological and fibrotic diseases | |
| EP2582682A4 (en) | METHOD FOR THE TREATMENT OF LUNG DISEASES | |
| NI201100155A (es) | Composiciones y métodos para el tratamiento prolongado con aminopiridinas | |
| Anurathapan et al. | Engineered T cells for cancer treatment | |
| EP2550004A4 (en) | HEPARANSULFATERSATZTHERAPIE | |
| GB2497453B (en) | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV | |
| NZ610891A (en) | Cd89 activation in therapy | |
| MX2012010714A (es) | Antagonistas de ccr3 de arilsulfonamida. | |
| BR112016013007A2 (pt) | Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf | |
| UA111520C2 (uk) | [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази | |
| UA107660C2 (ru) | Антагонисты арилсульфонамидов ccr3 |